Abstract 553P
Background
Next generation sequencing (NGS) has revolutionised the diagnosis of non-small cell lung cancer (NSCLC) yet it is resource-intensive. Exclusionary testing followed by NGS has been advocated as a cost-effective approach in Asians where EGFR mutations are prevalent. Herein we investigated the approach of plasma EGFR (pEGFR) followed by tissue NGS and compared it to upfront tissue NGS in terms of mutation detection and clinical outcome in a real world setting in Hong Kong.
Methods
We retrospectively reviewed 222 patients diagnosed with advanced NSCLC from October 2021 to April 2023, including 145 cases that performed upfront tissue NGS without prior pEGFR (group 1) and 77 cases that underwent pEGFR (Cobas v2) first. Among the latter group, 48 with positive pEGFR (group 2a) started target therapy while 29 with negative pEGFR (group 2b) proceeded further tissue NGS (Oncomine precision assay). Genomic alterations and clinical data were compared among these approaches.
Results
The median age was 70, 72 and 76 years old for group 1, 2a and 2b respectively. Extrathoracic disease was found in 54%, 90% and 41% of patients in each group. Regarding genomic alterations detected by tissue NGS, sensitising EGFR mutations were found in 39% of cases in group 1, compared to only 7% in group 2b (OR 0.11, p=0.001). Additional driver mutations (EGFR exon 20 insertion, T790M, ALK, BRAF, MET exon 14 skipping, ERBB2 exon 20 insertion and KRAS) were found in 27% of group 1 cases, but up to 52% in group 2b (OR 2.92, p=0.008). For patients with EGFR mutations detected by tissue NGS, 41% had concurrent TP53 or PIK3CA mutation, which are predictive markers. The median time from radiological diagnosis to treatment initiation was 18 days for patients with positive pEGFR compared with 41 days for the counterparts underwent tissue NGS.
Conclusions
The pathway of pEGFR preceding tissue NGS allows early detection of druggable EGFR mutations and initiation of target therapy for patients with extrathoracic NSCLC but lacks simultaneous detection of predictive markers. The liquid-first approach enhances the yield of rare mutations by tissue NGS which is resource-dependent. It benefits regions where tissue biopsy is a rate limiting factor and EGFR mutations are prevalent.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
183P - Final analysis of phase II clinical study evaluating the safety and effectiveness of neoadjuvant S-1 + oxaliplatin combination therapy for older patients with locally advanced gastric cancer
Presenter: Eiji Oki
Session: Poster Display
Resources:
Abstract
184P - Neutropenia as a predictive and prognostic factor in nanoliposomal-irinotecan/fluorouracil/leucovorin therapy for pancreatic cancer: Findings from the NAPOLEON-2 study (NN-2301)
Presenter: Yuki Sonoda
Session: Poster Display
Resources:
Abstract
185P - Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
186P - Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial
Presenter: Xiaoting Ma
Session: Poster Display
Resources:
Abstract
187P - Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)
Presenter: Yongguang Wei
Session: Poster Display
Resources:
Abstract
188P - Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Margherita Rimini
Session: Poster Display
Resources:
Abstract
189P - Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Shun Yamamoto
Session: Poster Display
Resources:
Abstract
190P - Perioperative camrelizumab combined with chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, single-center, phase II clinical trial
Presenter: Jiaxing He
Session: Poster Display
Resources:
Abstract
191P - Predictive value of CXCR6 expression in gastric cancer survival and immune modulation
Presenter: Song-Hee han
Session: Poster Display
Resources:
Abstract
192P - Antiangiogenesis-related adverse events (ARAE) to predict efficacy in patients with advanced gastric cancer (AGC) treated with apatinib + chemotherapy: Results from two prospective studies
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract